Answers are grounded in this paper and cite their sources.
Outcomes after complete resection of stage I lung adenocarcinoma vary widely, and anatomical stage alone does not explain this variation. Competing-risk methods are rarely applied in single-centre series, although most deaths after resection of stage I disease are not caused by recurrence. We aimed to determine which clinicopathological factors remain independently associated with recurrence and with death when analysed together, and to estimate the risk of recurrence while treating death without recurrence as a competing event. We retrospectively reviewed 184 patients with pathological stage I lung adenocarcinoma resected between January 2016 and December 2023 at a single centre; 26 were excluded. Overall and disease-free survival were estimated by the Kaplan-Meier method and compared by log-rank test. Cox proportional hazards models were fitted for each endpoint, containing histological grade, lymphovascular invasion, tumour size, extent of resection, age, sex and, for overall survival, adjuvant therapy. Recurrence was additionally analysed with the Aalen-Johansen estimator and a Fine-Gray model, treating death without recurrence as the competing event. A total of 158 patients were analysed; 118 underwent lobar and 40 sublobar resection. Median follow-up was 84.9 months. Recurrence occurred in 31 patients (19.6%) and 41 (25.9%) died. 5-year overall and disease-free survival were 79.2% and 66.1%. Lymphovascular invasion was independently associated with worse overall survival (hazard ratio 3.24, 95% confidence interval 1.63 to 6.45) and disease-free survival (2.35, 1.34 to 4.13), whereas histological grade and extent of resection were not. Twenty-eight of 41 deaths (68.3%) occurred without recurrence, and 13 deaths (31.7%) were attributed to lung cancer. Cumulative incidence of recurrence at five years was 18.4% versus a Kaplan-Meier estimate of 20.4%. Nearly half of all recurrences occurred more than 24 months after surgery. Analysed together, lymphovascular invasion was the only factor independently associated with both recurrence and death. These data align with the randomised evidence rather than with series favouring lobectomy in high-risk disease. Most deaths occurred without recurrence and most were not caused by lung cancer, which affects how recurrence risk should be estimated, and nearly half of all recurrences occurred more than two years after surgery, arguing against surveillance limited to the early postoperative period. Confirmation in multicentre cohorts, and prospective collection of pulmonary function data, are required. Not applicable.
No takes yet. Share an insight, caveat, or question.
ERTAN et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: